Loading company…
Zhongmo Medical develops gene therapies for rare inherited eye diseases.
Founded in 2019 and based in Wuhan, China, Zhongmo Medical develops gene therapies for rare ophthalmic genetic diseases. Its pipeline includes candidates for juvenile retinoschisis and retinitis pigmentosa, and its lead retinoschisis program has entered clinical trials. In October 2025, it raised angel funding from Wuhan Jingkai Industrial Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in